{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:40:15Z","timestamp":1793367615707,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100016827","name":"Deciphera Pharmaceuticals","doi-asserted-by":"publisher","award":["Deciphera Pharmaceuticals"],"award-info":[{"award-number":["Deciphera Pharmaceuticals"]}],"id":[{"id":"10.13039\/100016827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11136-026-04162-7","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T09:16:59Z","timestamp":1769937419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mixed-Methods to Define Meaningful Change using Exit Interview and Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT)"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3566-1004","authenticated-orcid":false,"given":"Heather L.","family":"Gelhorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn N.","family":"Cutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Harrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsion","family":"Fikre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Zeringo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Van De Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bernthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"key":"4162_CR1","unstructured":"de Saint Aubain Somerhausen, N. S., & van de Rijn, M. (2013). Tenosynovial giant cell tumor: localized type, diffuse type. In C. D. M. Fletcher, J. A. Bridge, P. C. W. Hogendoorn, & F. Mertens (Eds.), WHO Classification of Tumours of Soft Tissue and Bone (4th ed., Vol. 5, pp. 100\u2013103). International Agency for Research on Cancer."},{"issue":"7","key":"4162_CR2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1302\/0301-620X.94B7.28927","volume":"94","author":"L van der Heijden","year":"2012","unstructured":"van der Heijden, L., Gibbons, C. L., Dijkstra, P. D., Kroep, J. R., van Rijswijk, C. S., Nout, R. A., Bradley, K. M., Athanasou, N. A., Hogendoorn, P. C., & van de Sande, M. A. (2012). The management of diffuse-type giant cell tumour (pigmented villonodular synovitis) and giant cell tumour of tendon sheath (nodular tenosynovitis). Journal of Bone and Joint Surgery. British Volume, 94(7), 882\u2013888. https:\/\/doi.org\/10.1302\/0301-620X.94B7.28927","journal-title":"Journal of Bone and Joint Surgery. British Volume"},{"key":"4162_CR3","unstructured":"Daiichi Sankyo. (2019). TURALIO (pexidartinib) capsules, for oral use. Prescribing Information. Retrieved April 2024 from https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Turalio&inline=true"},{"issue":"4","key":"4162_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.clinthera.2016.03.008","volume":"38","author":"HL Gelhorn","year":"2016","unstructured":"Gelhorn, H. L., Tong, S., McQuarrie, K., Vernon, C., Hanlon, J., Maclaine, G., Lenderking, W., Ye, X., Speck, R. M., Lackman, R. D., Bukata, S. V., Healey, J. H., Keedy, V. L., Anthony, S. P., Wagner, A. J., Von Hoff, D. D., Singh, A. S., Becerra, C. R., Hsu, H. H., & Tap, W. D. (2016). Patient-reported symptoms of tenosynovial giant cell tumors. Clinical Therapeutics, 38(4), 778\u2013793. https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.008","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"4162_CR5","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1093\/oncolo\/oyad011","volume":"28","author":"E Palmerini","year":"2023","unstructured":"Palmerini, E., Healey, J. H., Bernthal, N. M., Bauer, S., Schreuder, H., Leithner, A., Martin-Broto, J., Gouin, F., Lopez-Bastida, J., Gelderblom, H., Staals, E. L., Mercier, F., Laeis, P., Ye, X., & van de Sande, M. (2023). Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-year analysis of patient-reported outcomes and treatment strategies. The Oncologist, 28(6), e425\u2013e435. https:\/\/doi.org\/10.1093\/oncolo\/oyad011","journal-title":"The Oncologist"},{"issue":"10445","key":"4162_CR6","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","volume":"403","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom, H., Bhadri, V., Stacchiotti, S., Bauer, S., Wagner, A. J., van de Sande, M., Bernthal, N. M., Lopez Pousa, A., Razak, A. A., Italiano, A., Ahmed, M., Le Cesne, A., Tinoco, G., Boye, K., Martin-Broto, J., Palmerini, E., Tafuto, S., Pratap, S., & Powers, B. C. (2024). Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 403(10445), 2709\u20132719. https:\/\/doi.org\/10.1016\/S0140-6736(24)00885-7","journal-title":"Lancet"},{"issue":"4","key":"4162_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17453674.2021.1922161","volume":"92","author":"M Sande","year":"2021","unstructured":"Sande, M., Tap, W. D., Gelhorn, H. L., Ye, X., Speck, R. M., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K., Martin-Broto, J., Wang, Q., Shuster, D., Gelderblom, H., & Healey, J. H. (2021). Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: Results from the ENLIVEN randomized clinical trial. Acta Orthopaedica, 92(4), 493\u2013499. https:\/\/doi.org\/10.1080\/17453674.2021.1922161","journal-title":"Acta Orthopaedica"},{"issue":"1","key":"4162_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0099-0","volume":"3","author":"HL Gelhorn","year":"2019","unstructured":"Gelhorn, H. L., Ye, X., Speck, R. M., Tong, S., Healey, J. H., Bukata, S. V., Lackman, R. D., Murray, L., Maclaine, G., Lenderking, W. R., Hsu, H. H., Lin, P. S., & Tap, W. D. (2019). The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS). Journal of Patient-Reported Outcomes, 3(1), Article 6. https:\/\/doi.org\/10.1186\/s41687-019-0099-0","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"1","key":"4162_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00217-6","volume":"4","author":"RM Speck","year":"2020","unstructured":"Speck, R. M., Ye, X., Bernthal, N. M., & Gelhorn, H. L. (2020). Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors. Journal of Patient-Reported Outcomes, 4(1), Article 61. https:\/\/doi.org\/10.1186\/s41687-020-00217-6","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"2","key":"4162_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/1078-0432.CCR-21-2007","volume":"28","author":"WD Tap","year":"2022","unstructured":"Tap, W. D., Singh, A. S., Anthony, S. P., Sterba, M., Zhang, C., Healey, J. H., Chmielowski, B., Cohn, A. L., Shapiro, G. I., Keedy, V. L., Wainberg, Z. A., Puzanov, I., Cote, G. M., Wagner, A. J., Braiteh, F., Sherman, E., Hsu, H. H., Peterfy, C., Gelhorn, H. L., & Tong-Starksen, S. (2022). Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT. Clinical Cancer Research, 28(2), 298\u2013307. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2007","journal-title":"Clinical Cancer Research"},{"issue":"5-6 Suppl A","key":"4162_CR11","first-page":"4S","volume":"10","author":"RS Keefe","year":"2013","unstructured":"Keefe, R. S., Kraemer, H. C., Epstein, R. S., Frank, E., Haynes, G., Laughren, T. P., McNulty, J., Reed, S. D., Sanchez, J., & Leon, A. C. (2013). Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innovations in Clinical Neuroscience, 10(5-6 Suppl A), 4S-19S.","journal-title":"Innovations in Clinical Neuroscience"},{"issue":"1","key":"4162_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/2168479015622667","volume":"50","author":"CD Coon","year":"2016","unstructured":"Coon, C. D., & Cappelleri, J. C. (2016). Interpreting change in scores on Patient-Reported Outcome Instruments. Therapeutic Innovation & Regulatory Science, 50(1), 22\u201329. https:\/\/doi.org\/10.1177\/2168479015622667","journal-title":"Therapeutic Innovation & Regulatory Science"},{"issue":"4","key":"4162_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407\u2013415. https:\/\/doi.org\/10.1016\/0197-2456(89)90005-6","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"4162_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1586\/erp.11.12","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod, L. D., Coon, C. D., Martin, S. A., Fehnel, S. E., & Hays, R. D. (2011). Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Review of Pharmacoeconomics & Outcomes Research, 11(2), 163\u2013169. https:\/\/doi.org\/10.1586\/erp.11.12","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research"},{"issue":"1","key":"4162_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton, H., Willgoss, T., Nelsen, L., Burbridge, C., Sully, K., Rofail, D., & Arbuckle, R. (2019). An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. Journal of Patient-Reported Outcomes, 3(1), Article 16. https:\/\/doi.org\/10.1186\/s41687-019-0100-y","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"11","key":"4162_CR16","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jbmr.4900","volume":"38","author":"SM de Jan Beur","year":"2023","unstructured":"de Jan Beur, S. M., Cimms, T., Nixon, A., Theodore-Oklota, C., Luca, D., Roberts, M. S., Egan, S., Graham, C. A., Hribal, E., Evans, C. J., Wood, S., & Williams, A. (2023). Burosumab improves patient-reported outcomes in adults with tumor-induced osteomalacia: Mixed-methods analysis. Journal of Bone and Mineral Research, 38(11), 1654\u20131664. https:\/\/doi.org\/10.1002\/jbmr.4900","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"4162_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s11136-022-03294-w","volume":"32","author":"C Dias-Barbosa","year":"2023","unstructured":"Dias-Barbosa, C., Puelles, J., Fofana, F., Gabriel, S., Rodriguez, D., Chavda, R., & Piketty, C. (2023). An explanatory sequential mixed-methods design to establish thresholds of within-individual meaningful change on a sleep disturbance numerical rating scale score in atopic dermatitis. Quality of Life Research, 32(3), 881\u2013893. https:\/\/doi.org\/10.1007\/s11136-022-03294-w","journal-title":"Quality of Life Research"},{"issue":"4","key":"4162_CR18","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s12325-024-02802-3","volume":"41","author":"A Rams","year":"2024","unstructured":"Rams, A., Baldasaro, J., Bunod, L., Delbecque, L., Strzok, S., Meunier, J., ElMaraghy, H., Sun, L., & Pierce, E. (2024). Assessing itch severity: Content validity and psychometric properties of a patient-reported pruritus numeric rating scale in atopic dermatitis. Advances in Therapy, 41(4), 1512\u20131525. https:\/\/doi.org\/10.1007\/s12325-024-02802-3","journal-title":"Advances in Therapy"},{"key":"4162_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.4534","author":"K Ezzedine","year":"2024","unstructured":"Ezzedine, K., Soliman, A. M., Camp, H. S., Ladd, M. K., Pokrzywinski, R., Coyne, K. S., Sen, R., Schlosser, B. J., Bae, J. M., & Hamzavi, I. (2024). Psychometric properties and meaningful change thresholds of the Vitiligo Area Scoring Index. JAMA Dermatology. https:\/\/doi.org\/10.1001\/jamadermatol.2024.4534","journal-title":"JAMA Dermatology"},{"issue":"5","key":"4162_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/ejh.13316","volume":"103","author":"K Sully","year":"2019","unstructured":"Sully, K., Trigg, A., Bonner, N., Moreno-Koehler, A., Trennery, C., Shah, N., Yucel, E., Panjabi, S., & Cocks, K. (2019). Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. European Journal of Haematology, 103(5), 500\u2013509. https:\/\/doi.org\/10.1111\/ejh.13316","journal-title":"European Journal of Haematology"},{"issue":"4","key":"4162_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/hex.14169","volume":"27","author":"S Zingelman","year":"2024","unstructured":"Zingelman, S., Cadilhac, D. A., Kim, J., Stone, M., Harvey, S., Unsworth, C., O\u2019Halloran, R., Hersh, D., Mainstone, K., & Wallace, S. J. (2024). \u2018A meaningful difference, but not ultimately the difference I would want\u2019: A mixed-methods approach to explore and benchmark clinically meaningful changes in aphasia recovery. Health Expectations, 27(4), Article e14169. https:\/\/doi.org\/10.1111\/hex.14169","journal-title":"Health Expectations"},{"key":"4162_CR22","unstructured":"Gerhardt, J. J., Cocchiarelle, L., & Lea, R. D. (2002). The practical guide to range of motion assessment. American Medical Association."},{"issue":"1","key":"4162_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-018-0037-6","volume":"2","author":"S Eremenco","year":"2017","unstructured":"Eremenco, S., Pease, S., Mann, S., & Berry, P. (2017). Patient-Reported Outcome (PRO) Consortium translation process: Consensus development of updated best practices. Journal of Patient-Reported Outcomes, 2(1), Article 12. https:\/\/doi.org\/10.1186\/s41687-018-0037-6","journal-title":"Journal of Patient-Reported Outcomes"},{"issue":"7","key":"4162_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker, D. M., Lamoureux, R. E., Stokes, J., Litcher-Kelly, L., Galipeau, N., Yaworsky, A., Solomon, J., & Shields, A. L. (2018). Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value in Health, 21(7), 839\u2013842. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014","journal-title":"Value in Health"},{"key":"4162_CR25","unstructured":"Atlas.ti 22 Windows - User Manual. Retrieved December 2024 from https:\/\/doc.atlasti.com\/ManualWin.v22\/ATLAS.ti_ManualWin.v22.pdf"},{"issue":"9","key":"4162_CR26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277\u20131288. https:\/\/doi.org\/10.1177\/1049732305276687","journal-title":"Qualitative Health Research"},{"key":"4162_CR27","unstructured":"Food and Drug Administration. (2023). Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Retrieved December 2024 from https:\/\/www.fda.gov\/media\/166830\/download"},{"issue":"2","key":"4162_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102\u2013109. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012","journal-title":"Journal of Clinical Epidemiology"},{"issue":"1","key":"4162_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1081\/copd-200050508","volume":"2","author":"NK Leidy","year":"2005","unstructured":"Leidy, N. K., & Wyrwich, K. W. (2005). Bridging the gap: Using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD, 2(1), 157\u2013165. https:\/\/doi.org\/10.1081\/copd-200050508","journal-title":"COPD"},{"issue":"1","key":"4162_CR30","doi-asserted-by":"publisher","DOI":"10.2196\/ijmr.9325","volume":"7","author":"MJ Mastboom","year":"2018","unstructured":"Mastboom, M. J., Planje, R., & van de Sande, M. A. (2018). The patient perspective on the impact of tenosynovial giant cell tumors on daily living: Crowdsourcing study on physical function and quality of life. Interactive Journal of Medical Research, 7(1), Article e4. https:\/\/doi.org\/10.2196\/ijmr.9325","journal-title":"Interactive Journal of Medical Research"},{"key":"4162_CR31","unstructured":"Deciphera Pharmaceuticals, LLC. ROMVIMZA (vimseltinib) capsules, for oral use [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219304s000lbl.pdf Revised February 2025."},{"issue":"10","key":"4162_CR32","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","volume":"30","author":"CB Terwee","year":"2021","unstructured":"Terwee, C. B., Peipert, J. D., Chapman, R., Lai, J. S., Terluin, B., Cella, D., Griffiths, P., & Mokkink, L. B. (2021). Minimal important change (MIC): A conceptual clarification and systematic review of MIC estimates of PROMIS measures. Quality of Life Research, 30(10), 2729\u20132754. https:\/\/doi.org\/10.1007\/s11136-021-02925-y","journal-title":"Quality of Life Research"}],"updated-by":[{"DOI":"10.1007\/s11136-026-04275-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000}}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-026-04162-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-026-04162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T05:28:18Z","timestamp":1779600498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-026-04162-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4162"],"URL":"https:\/\/doi.org\/10.1007\/s11136-026-04162-7","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Multiple formatting errors related to spacing, capitalization and table and figure headers and footers are corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11136-026-04275-z","URL":"https:\/\/doi.org\/10.1007\/s11136-026-04275-z","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Heather Gelhorn, Katelyn Cutts, Tsion Fikre and Yipin Han work for Evidera, a scientific research consultancy. Evidera was paid to conduct this work by Deciphera Pharmaceuticals, LLC. Brooke Harrow, Christopher Tait, Amanda Saunders, Nicholas A Zeringo are employees of Deciphera Pharmaceuticals, LLC. Michiel van de Sande reports institutional research funding from Implantcast GmbH and consulting\/advisory roles for Merck, SynOx, and Deciphera Pharmaceuticals, LLC. Dr. Tap reports personal fees from: Daiichi Sankyo, Deciphera, Servier, Bayer Pharmaceuticals, Cogent, Amgen, AmMax Bio, Boehringer Ingelheim, BioAtla, Inhibrx, PharmaEssentia, Avacta, Ipsen, Sonata, Abbisko, Aadi, IMGT, Ikena, Curadev, Ratio, C4 Therapeutcis, Synox, Recordati. In addition, Dr. Tap has a patent Companion Diagnostic for CDK4 inhibitors\u201414\/854,329 pending to MSKCC\/SKI, and a patent Enigma and CDH18 as companion Diagnostics for CDK4 inhibition \u2013 SKI2016-021\u201303 issued to MSKCC\/SKI and Scientific Advisory Board\u2014Certis Oncology Solutions, Stock Ownership, Co-Founder\u2014Atropos Therapeutics, Stock Ownership, Scientific Advisory Board Innova Therapeutics Strategic Advisory Board Osteosarcoma Institute, and Chair, Scientific Advisory Board Avacta. Hans Gelderblom reports Institutional financial compensation for entering patients in TGCT studies form AmmaxBio, Deciphera, Abbisko and SynOx Therapeutics. Nicholas Bernthal reports Scientific Advisor to Daiichi Sankyo, Merck, Deciphera, ZimmerBiomet, Onkos Surgical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by an institutional review board or ethics committee at each clinical site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"57"}}